Skip to main content

Table 4 Adverse events reported among participants enrolled in 2017–2018 therapeutic efficacy study, Burkina Faso

From: Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018

  Niangoloko Nanoro Gourcy
AL (n = 116) DP (n = 118) AL (n = 117) DP (n = 114) AL (n = 120) DP (n = 118)
Itchiness 0 0 0 0 1 0
Otitis media 1 0 0 0 0 0
Cough 14 14 4 1 3 2
Abdominal pain 2 7 2 5 0 1
Skin rash 0 2 2 0 0 1
Oral thrush 0 0 0 0 0 0
Furunculosis 0 1 0 0 0 0
Vomiting 12 23 15 18 6 13
Death 0 0 0 0 1 0
  1. AL artemether lumefantrine, DP dihydroartemisinin piperaquine